Placebo-Controlled, Double-Blind, First-In-Human, Ascending Single Dose and Multiple Dose, Healthy Subject Study of Intravenous-Administered SelG1, a Humanized Anti-P-Selectin Antibody in Development for Sickle Cell Disease
Blood（2013）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined